Natixis Advisors
SWTX

Natixis Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Natixis Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,855
Closed -$782K – 1503
2022
Q1 		$782K Sell
13,855
-4
-0% -$229 ﹤0.01% 1185
2021
Q4 		$859K Sell
13,859
-756
-5% -$50K ﹤0.01% 1147
2021
Q3 		$927K Buy
14,615
+59
+0.4% +$4.55K ﹤0.01% 1107
2021
Q2 		$1.2M Buy
14,556
+2,404
+20% +$183K 0.01% 1056
2021
Q1 		$894K Buy
+12,152
New +$952K ﹤0.01% 1079

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Natixis Advisors's SWTX Position: Q2 2022 in Review

Natixis Advisors sold out of SpringWorks Therapeutics (SWTX) in Q2 2022, closing a stake of 13,855 shares — an estimated $782K sold.

Natixis Advisors first reported a position in SWTX in Q1 2021 and held it in 5 quarters. The position peaked at $1.2M in Q2 2021. 143 funds tracked by Wall St. Rank hold SWTX as of Q2 2022.

  • Natixis Advisors reported no remaining SpringWorks Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Natixis Advisors sold 13,855 SpringWorks Therapeutics shares in Q2 2022, an estimated $782K.
  • Natixis Advisors first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 5 quarters.
  • Natixis Advisors's SpringWorks Therapeutics position peaked at $1.2M in Q2 2021.
  • 143 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2022.

Based on Natixis Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.